CD133 Targeted PVP/PMMA Microparticle Incorporating Levamisole for the Treatment of Ovarian Cancer

Levamisole (LEVA) is used to treat worm infections, but it can also inhibit cancer cell growth by inhibiting the aldehyde dehydrogenase pathway. Therefore, here, we developed a drug carrier targeting CD133, a biomarker overexpressed in ovarian cancer cells. The particle structure and cytotoxicity of...

Full description

Bibliographic Details
Main Authors: Yu-Chi Wang, Meng-Yi Bai, Ying-Ting Yeh, Sung-Ling Tang, Mu-Hsien Yu
Format: Article
Language:English
Published: MDPI AG 2020-02-01
Series:Polymers
Subjects:
Online Access:https://www.mdpi.com/2073-4360/12/2/479
id doaj-ff95fdd582bd4a9e86087f2c62ee4a8b
record_format Article
spelling doaj-ff95fdd582bd4a9e86087f2c62ee4a8b2020-11-25T02:16:10ZengMDPI AGPolymers2073-43602020-02-0112247910.3390/polym12020479polym12020479CD133 Targeted PVP/PMMA Microparticle Incorporating Levamisole for the Treatment of Ovarian CancerYu-Chi Wang0Meng-Yi Bai1Ying-Ting Yeh2Sung-Ling Tang3Mu-Hsien Yu4Department of Obstetric and Gynecology, Tri-Service General Hospital, National Defense Medical Center, Taipei 10607, TaiwanGraduate Institute of Biomedical Engineering, National Taiwan University of Science and Technology, Taipei 10607, TaiwanGraduate Institute of Biomedical Engineering, National Taiwan University of Science and Technology, Taipei 10607, TaiwanDepartment of Pharmacy Practice, Tri-Service General Hospital, Taipei 10607, TaiwanDepartment of Obstetric and Gynecology, Tri-Service General Hospital, National Defense Medical Center, Taipei 10607, TaiwanLevamisole (LEVA) is used to treat worm infections, but it can also inhibit cancer cell growth by inhibiting the aldehyde dehydrogenase pathway. Therefore, here, we developed a drug carrier targeting CD133, a biomarker overexpressed in ovarian cancer cells. The particle structure and cytotoxicity of the prepared LEVA-containing particles—called LEVA/PVP/PMMA microparticles (MPs) (because it used matrix material polyvinylpyrrolidone (PVP) and poly(methylmethacrylate) (PMMA))—were investigated in the ovarian cancer cell lines SKOV-3 and CP70. The particle size of the MPs was determined to be 1.0−1.5 µm and to be monodispersed. The hydrophilic property of PVP created a porous MP surface after the MPs were soaked in water for 20 min, which aided the leaching of the hydrophilic LEVA out of the MPs. The encapsulation efficiency of LEVA/PVP/PMMA MPs could reach up to 20%. Free-form LEVA released 50% of drugs in <1 h and 90% of drugs in 1 day, whereas the drug release rate of LEVA/PVP/PMMA MPs was much slower; 50% released in 4 h and only 70% of drugs released in 1 day. In the in vitro cell model test, 5 mM free-form LEVA and 0.1 g/mL CD133 targeted LEVA/PVP/PMMA MPs reduced SKOV-3 cell viability by 60%; 0.1 g/mL LEVA/PVP/PMMA MPs was equivalent to a similar dosage of the free drug. In addition, the cytotoxicity of CD133-conjugated LEVA/PVP/PMMA MPs shows a different cytotoxicity response toward cell lines. For SKOV-3 cells, treatment with free-form LEVA or CD133-conjugated LEVA/PVP/PMMA MPs exerted dose-dependent cytotoxic effects on SKOV-3 cell viability. However, CD133-conjugated LEVA/PVP/PMMA MPs demonstrated no significant dose-dependent cytotoxic efficacy toward CP70 cells.https://www.mdpi.com/2073-4360/12/2/479levamisoledrug carriermicroparticleovarian cancerelectrospray
collection DOAJ
language English
format Article
sources DOAJ
author Yu-Chi Wang
Meng-Yi Bai
Ying-Ting Yeh
Sung-Ling Tang
Mu-Hsien Yu
spellingShingle Yu-Chi Wang
Meng-Yi Bai
Ying-Ting Yeh
Sung-Ling Tang
Mu-Hsien Yu
CD133 Targeted PVP/PMMA Microparticle Incorporating Levamisole for the Treatment of Ovarian Cancer
Polymers
levamisole
drug carrier
microparticle
ovarian cancer
electrospray
author_facet Yu-Chi Wang
Meng-Yi Bai
Ying-Ting Yeh
Sung-Ling Tang
Mu-Hsien Yu
author_sort Yu-Chi Wang
title CD133 Targeted PVP/PMMA Microparticle Incorporating Levamisole for the Treatment of Ovarian Cancer
title_short CD133 Targeted PVP/PMMA Microparticle Incorporating Levamisole for the Treatment of Ovarian Cancer
title_full CD133 Targeted PVP/PMMA Microparticle Incorporating Levamisole for the Treatment of Ovarian Cancer
title_fullStr CD133 Targeted PVP/PMMA Microparticle Incorporating Levamisole for the Treatment of Ovarian Cancer
title_full_unstemmed CD133 Targeted PVP/PMMA Microparticle Incorporating Levamisole for the Treatment of Ovarian Cancer
title_sort cd133 targeted pvp/pmma microparticle incorporating levamisole for the treatment of ovarian cancer
publisher MDPI AG
series Polymers
issn 2073-4360
publishDate 2020-02-01
description Levamisole (LEVA) is used to treat worm infections, but it can also inhibit cancer cell growth by inhibiting the aldehyde dehydrogenase pathway. Therefore, here, we developed a drug carrier targeting CD133, a biomarker overexpressed in ovarian cancer cells. The particle structure and cytotoxicity of the prepared LEVA-containing particles—called LEVA/PVP/PMMA microparticles (MPs) (because it used matrix material polyvinylpyrrolidone (PVP) and poly(methylmethacrylate) (PMMA))—were investigated in the ovarian cancer cell lines SKOV-3 and CP70. The particle size of the MPs was determined to be 1.0−1.5 µm and to be monodispersed. The hydrophilic property of PVP created a porous MP surface after the MPs were soaked in water for 20 min, which aided the leaching of the hydrophilic LEVA out of the MPs. The encapsulation efficiency of LEVA/PVP/PMMA MPs could reach up to 20%. Free-form LEVA released 50% of drugs in <1 h and 90% of drugs in 1 day, whereas the drug release rate of LEVA/PVP/PMMA MPs was much slower; 50% released in 4 h and only 70% of drugs released in 1 day. In the in vitro cell model test, 5 mM free-form LEVA and 0.1 g/mL CD133 targeted LEVA/PVP/PMMA MPs reduced SKOV-3 cell viability by 60%; 0.1 g/mL LEVA/PVP/PMMA MPs was equivalent to a similar dosage of the free drug. In addition, the cytotoxicity of CD133-conjugated LEVA/PVP/PMMA MPs shows a different cytotoxicity response toward cell lines. For SKOV-3 cells, treatment with free-form LEVA or CD133-conjugated LEVA/PVP/PMMA MPs exerted dose-dependent cytotoxic effects on SKOV-3 cell viability. However, CD133-conjugated LEVA/PVP/PMMA MPs demonstrated no significant dose-dependent cytotoxic efficacy toward CP70 cells.
topic levamisole
drug carrier
microparticle
ovarian cancer
electrospray
url https://www.mdpi.com/2073-4360/12/2/479
work_keys_str_mv AT yuchiwang cd133targetedpvppmmamicroparticleincorporatinglevamisoleforthetreatmentofovariancancer
AT mengyibai cd133targetedpvppmmamicroparticleincorporatinglevamisoleforthetreatmentofovariancancer
AT yingtingyeh cd133targetedpvppmmamicroparticleincorporatinglevamisoleforthetreatmentofovariancancer
AT sunglingtang cd133targetedpvppmmamicroparticleincorporatinglevamisoleforthetreatmentofovariancancer
AT muhsienyu cd133targetedpvppmmamicroparticleincorporatinglevamisoleforthetreatmentofovariancancer
_version_ 1724892272966762496